BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
BEGIN:VEVENT
UID:194@biocityturku.fi
DTSTART;TZID=Europe/Helsinki:20190121T090000
DTEND;TZID=Europe/Helsinki:20190121T140000
DTSTAMP:20231013T060903Z
URL:https://biocityturku.fi/events/translating-molecules-to-treatments-ii/
SUMMARY:TRANSLATING MOLECULES TO TREATMENTS II
DESCRIPTION:DRUG DEVELOPMENT AND DIAGNOSTICS MINI-SYMPOSIUM\nTRANSLATING MO
 LECULES TO TREATMENTS II\n9.00-9.10 Opening words by Professor Lea Sistone
 n\n9.10-10.00 Thomas Kirkegaard Jensen Orphazyme - From Biology to Bedside
 \nThomas Kirkegaard Jensen is a PhD and Chief Scientific Officer of Orphaz
 yme ApS in Denmark. Orphazyme develops new therapies for patients sufferin
 g from protein-misfolding diseases with no or limited treatment options av
 ailable. Orphazyme was founded on the initial discovery made by Thomas dur
 ing his doctoral studies in the laboratory of Professor Marja Jäättelä 
 at the Danish Cancer Society\, in which they found that the molecular chap
 erone\, heat shock protein 70\, reverts the pathology associated with lyso
 somal storage diseases. Based on this finding the company develops of new 
 treatments for lysosomal storage diseases.\n10.00-10.20 Coffee break\n10.2
 0-11.10 Rajwinder Lehal From Cell to Cellestia - Transition of a PhD Proje
 ct Into a Drug Development Company\nRajwinder Lehal is a PhD and co-founde
 r of Cellestia Biotech AG in Switzerland. The aim of Cellestia Biotech is 
 to develop innovative therapeutics for cancer treatment. At Cellestia Biot
 ech\, he is Chief Scientific Officer and serves on the Board of Directors.
  Cellestia Biotech has developed a targeted therapy designed to treat canc
 ers resulting from a mutation of the Notch gene. Molecule CB-103\, discove
 red by Rajwinder Lehal during his doctoral studies in Professor Freddy Rad
 tke's laboratory at EPFL\, cuts off Notch signals leading to cell death of
  cancer cells.\n11.10-12.00 Mads Daugaard Leveraging Placental Malaria Tro
 pism for Cancer Therapeutic and Diagnostic Applications\nMads Daugaard is 
 an Assistant Professor and group leader at Vancouver Prostate Centre at Un
 iversity of British Columbia and the Co-founder and Chairman of the Board 
 of Directors of three biotech companies\; VAR2 Pharmaceuticals\, OncoMal a
 nd VarCT Diagnostics in Canada. Mads is a molecular biologist specialized 
 in tumour-associated stress signaling pathways and tumour targeting system
 s. His research focuses on alternative polyadenylation of mRNAs\, chromati
 n context-dependent DNA repair\, development of resistance to chemotherapy
 \, and immune evasion mechanisms in cancer. Another aspect of Mads’ rese
 arch relates to discovery and development of novel tumour targeting system
 s based on parasite-derived recombinant proteins relevant for therapeutic 
 and diagnostic applications in cancer.\n12.30-14.00 Round table lunch with
  speakers\nRound table discussions including lunch for students and postdo
 cs in groups of 10 students/postdocs per speaker. The 30 first to register
  will be admitted.\nRegister before Friday January 11th  at https://surve
 y.abo.fi/lomakkeet/10837/lomake.html\nFor more information\, contact Annik
 a Meinander\, e-mail: annika.meinander@abo.fi\n\n&nbsp\;
CATEGORIES:BiocityTurku events,Other events
LOCATION:#_LOCATIONNAME\, #_LOCATIONFULLLINE\, #_LOCATIONCOUNTRY
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=#_LOCATIONFULLLINE\, #_LOCA
 TIONCOUNTRY;X-APPLE-RADIUS=100;X-TITLE=#_LOCATIONNAME:geo:0,0
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
X-LIC-LOCATION:Europe/Helsinki
BEGIN:STANDARD
DTSTART:20181028T030000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
END:STANDARD
END:VTIMEZONE
END:VCALENDAR